Pharvaris (NASDAQ:PHVS - Get Free Report) shares shot up 8% during mid-day trading on Monday . The stock traded as high as $20.69 and last traded at $20.69. 23,719 shares were traded during mid-day trading, a decline of 77% from the average session volume of 103,124 shares. The stock had previously closed at $19.16.
Wall Street Analyst Weigh In
Several analysts have weighed in on PHVS shares. JMP Securities boosted their target price on shares of Pharvaris from $49.00 to $50.00 and gave the company a "market outperform" rating in a research note on Thursday, April 11th. Wedbush reiterated an "outperform" rating and set a $35.00 target price on shares of Pharvaris in a research note on Thursday, April 11th. Finally, Morgan Stanley reiterated an "overweight" rating and set a $34.00 target price on shares of Pharvaris in a research note on Monday.
Check Out Our Latest Stock Report on PHVS
Pharvaris Stock Up 8.9 %
The firm's 50-day moving average price is $23.85 and its 200 day moving average price is $23.33. The firm has a market cap of $664.50 million, a P/E ratio of -7.35 and a beta of -3.12.
Hedge Funds Weigh In On Pharvaris
Several institutional investors have recently modified their holdings of the company. Walleye Capital LLC grew its position in shares of Pharvaris by 15.2% during the third quarter. Walleye Capital LLC now owns 81,017 shares of the company's stock worth $1,691,000 after acquiring an additional 10,691 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in Pharvaris in the 3rd quarter valued at about $812,000. Blackstone Inc. bought a new position in Pharvaris in the 4th quarter valued at about $2,805,000. Vivo Capital LLC bought a new position in Pharvaris in the 4th quarter valued at about $7,994,000. Finally, venBio Partners LLC grew its position in Pharvaris by 15.4% in the 4th quarter. venBio Partners LLC now owns 4,919,504 shares of the company's stock valued at $137,992,000 after buying an additional 654,832 shares in the last quarter.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).
Featured Articles
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
